New York, NY (October 4 2021) – LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at the European College of Neuropsychopharmacology (ECNP) 2021 conference, held […]
MONTREAL (CANADA) – October 25, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Chief Development Officer (CDO), effective immediately. With over 20 years of experience and a proven track record in the pharmaceutical and biotechnology industry, Dr. Harvey will
Los Angeles CA – October 19, 2021 – Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announced today that the first patient has been enrolled in trial HS01, a phase 1b multicenter, randomized, double-blind, placebo-controlled study of topical AT193 for the treatment of mild-to-moderate hidradenitis suppurativa (HS). The study
Azora Therapeutics Enrolls First Patient in Clinical Trial of AT-193 Read More »
New York, NY (October 4 2021) – LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at the European College of Neuropsychopharmacology (ECNP) 2021 conference, held
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will
